Methylation, Gene Expression, and Risk Genotypes at the TERT‐CLPTM1L Locus in Cervical Cancer

Dhanya Ramachandran,Qianqian Mao,Dandan Liao,Maud Kamal,Peter Schürmann,Rieke Eisenblätter,Robert Geffers,Balazs Balint,Lolita Lecompte,Nicolas Servant,Linda Larbi Chérif,Constance Lamy,Sylvain Baulande,Patricia Legoix,Christophe Le Tourneau,Aurélien Latouche,Peter Hillemanns,Suzy Scholl,Thilo Dörk
DOI: https://doi.org/10.1002/mc.23822
2024-10-02
Molecular Carcinogenesis
Abstract:The reverse transcriptase subunit of telomerase, TERT, is frequently activated in high‐grade dysplasia and invasive cancers of the uterine cervix. Telomerase activation through hypomethylation of the TERT promoter holds promise as a biomarker for cervical cancer progression, however, specific CpG sites involved in cervical cancer risk remain to be fully defined. A recent genome‐wide association study on cervical cancer identified genetic polymorphisms at 5p13.33 (close to TERT‐CLPTM1L) but the underlying mechanisms are undetermined. We investigated 529 CpG sites within the TERT promoter region and 3 CpG islands nearby, and 21 CpG sites within CLPTM1L in 190 bisulfite‐converted cervical tumor DNA samples from BioRAIDs (NCT02428842). We identified eight CpG sites within TERT intron 2 where methylation was significantly associated with the genotypes of cervical cancer risk variants rs27070 and rs459961 in cervical tumors after multiple testing correction (p
oncology,biochemistry & molecular biology
What problem does this paper attempt to address?